Research Archives - Page 3 of 3 - Piauhy

Research

October 30, 2021

Autoimmune diseases and cannabis sativa

Autoimmune diseases are a group of different diseases that originate from the fact that the immune system starts to produce antibodies against the components of our […]
October 18, 2021

The endocannabinoid system

The endocannabinoid system is formed by cannabinoid receptors, endocannabinoids, metabolizing enzymes, and the membrane transporter
October 6, 2021

Piauhy Labs opens its research facility at Biocant Park

The medical Cannabis company is set to begin its new research in the Science and Technology Park located in Cantanhede, center of Portugal.
September 27, 2021

Alzheimer’s | A review

Neurodegenerative diseases pose a major threat to human health. These age-dependent disorders are becoming increasingly prevalent, in part because the elderly population has increased in recent […]
September 21, 2021

Epilepsy

Epilepsy is a disease characterized by a recurrent predisposition to epileptic seizures. It is a disease with neurobiological, cognitive, psychological and social consequences. Epilepsy is a […]
September 14, 2021

Sleep disorders and the medicinal use of Cannabis sativa

Sleeping is a homeostatic need of our organism, which means that it allows us to maintain the balance of our biological system, just like eating or […]
August 26, 2021

The Cannabis sativa plant beneficial properties

The Cannabis sativa plant, among its different species, has a complex matrix with more than at least 550 substances, including terpenes, carbohydrates, fatty acids and their […]
July 22, 2021

The Chemistry of Terpenes and cannabinoids synergy

The set of chemical reactions that constantly occur in cells is called metabolism. Plant cell metabolism is related to the various chemical reactions that occur in […]
May 4, 2021

Piauhy Labs announces its latest funding round led by Migration Capital

LISBON, Portugal, May 4, 2021 | PRNewswire | Piauhy Labs, one of Portugal’s leading biotech & medical cannabis firms has completed its latest funding round led by Migration Capital, […]